Display options
Cite
Hall WA, Colbert LE, Nickleach D, et al. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol. 2014;5(2):77-85doi: 10.3978/j.issn.2078-6891.2014.001.
Hall, W. A., Colbert, L. E., Nickleach, D., Switchenko, J., Liu, Y., Gillespie, T., Lipscomb, J., Hardy, C., Kooby, D. A., Prabhu, R. S., Kauh, J., & Landry, J. C. (2014). The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Journal of gastrointestinal oncology, 5(2), 77-85. https://doi.org/10.3978/j.issn.2078-6891.2014.001
Hall, William A, et al. "The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma." Journal of gastrointestinal oncology vol. 5,2 (2014): 77-85. doi: https://doi.org/10.3978/j.issn.2078-6891.2014.001
Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, Kauh J, Landry JC. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol. 2014 Apr;5(2):77-85. doi: 10.3978/j.issn.2078-6891.2014.001. PMID: 24772334; PMCID: PMC3999628.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2014 Apr;5(2):77-85. doi: 10.3978/j.issn.2078-6891.2014.001.

The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.

Journal of gastrointestinal oncology

William A Hall, Lauren E Colbert, Dana Nickleach, Jeffrey Switchenko, Yuan Liu, Theresa Gillespie, Joseph Lipscomb, Claire Hardy, David A Kooby, Roshan S Prabhu, John Kauh, Jerome C Landry

Affiliations

  1. 1 Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA ; 2 Biostatistics & Bioinformatics Shared Resource at Winship Cancer Institute, Atlanta, GA, USA ; 3 Department of Surgery and Winship Cancer Institute, Emory University, Atlanta, GA, USA ; 4 Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA ; 5 Rollins School of Public Health and Winship Cancer Institute, Atlanta, GA, USA ; 6 Department of Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.

PMID: 24772334 PMCID: PMC3999628 DOI: 10.3978/j.issn.2078-6891.2014.001

Abstract

PURPOSE: Radiation therapy (RT) dose escalation in unresectable pancreatic adenocarcinoma (PAC) remains investigational. We examined the association between total RT dose and overall survival (OS) in patients with unresectable PAC.

METHODS AND MATERIALS: National cancer data base (NCDB) data were obtained for patients who underwent definitive chemotherapy and RT (chemo-RT) for unresectable PAC. Univariate (UV) and multivariate (MV) survival analysis were performed along with Kaplan-Meier (KM) estimates for incremental RT dose levels.

RESULTS: A total of 977 analyzable patients met inclusion criteria. Median tumor size was 4.0 cm (0.3-40 cm) and median RT dose was 45 Gy. Median OS was 10 months (95% CI, 9-10 months). On MV analysis RT dose <30 Gy [HR, 2.38 (95% CI, 1.85-3.07); P<0.001] and RT dose ≥30 to <40 Gy [HR, 1.41 (95% CI, 1.04-1.91); P=0.026] were associated with lower OS when compared with dose ≥55 Gy. Patients receiving RT doses from 40 to <45, 45 to <50, 50 to <55, and ≥55 Gy did not differ in OS.

CONCLUSIONS: Lack of benefit to OS with conventionally delivered RT above 40 Gy is shown. Optimal RT dose escalation methods in unresectable PAC remain an important subject for investigation in prospective clinical trials.

Keywords: PAC and intensity modulated radiation therapy (IMRT); PAC and radiation therapy (RT); RT dose in unresectable pancreatic cancer; Radiation dose escalation pancreatic cancer; dose response pancreatic cancer; radiation dose escalation in pancreatic adenocarcinoma (PAC); unresectable pancreatic cancer

References

  1. J Clin Oncol. 2009 Apr 10;27(11):1806-13 - PubMed
  2. Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 - PubMed
  3. Cancer. 1981 Oct 15;48(8):1705-10 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):102-7 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1166-71 - PubMed
  6. J Clin Oncol. 2007 Jan 20;25(3):326-31 - PubMed
  7. Ann Oncol. 2008 Sep;19(9):1592-9 - PubMed
  8. J Surg Oncol. 2004 Jan;85(1):1-3 - PubMed
  9. Radiother Oncol. 2005 Jul;76(1):48-53 - PubMed
  10. Cancer. 2009 Feb 1;115(3):665-72 - PubMed
  11. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1383-90 - PubMed
  12. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1355-64 - PubMed
  13. Cancer. 2007 Jul 1;110(1):47-55 - PubMed
  14. Cancer. 2000 Dec 1;89(11):2222-9 - PubMed
  15. PLoS Med. 2010 Apr 20;7(4):e1000267 - PubMed
  16. Cancer. 2014 Feb 15;120(4):499-506 - PubMed
  17. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8 - PubMed
  20. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e615-22 - PubMed
  21. J Clin Oncol. 2001 Nov 15;19(22):4202-8 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21 - PubMed
  23. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16 - PubMed

Publication Types

Grant support